September 17, 2013
After a product shortage, Adequan® IM has been released to the market and is being resupplied to veterinarians.
Adequan (polysulfated glycosaminoglycan) is the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses.
Manufactured by Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., there was a brief interruption in supply caused by significant renovations and upgrades to Luitpold's New York facility to meet enhanced quality standards and address observations made by the FDA.
According to a release sent by Luitpold, shipments were received by veterinarians on September 13.
"Adequan® product supply remains limited and the initial shipments will not fully satisfy market demand," the release said in part. "Luitpold made significant investments in upgrading its manufacturing facilities earlier this year. The time spent making these upgrades impacted our ability to keep up with demand. We are working diligently to release additional product to the market and will provide updates as they become available. Quality and integrity remain our highest priorities."
To find more information visit www.adequan.com.
Louitpold and Adequan are corporate sponsors of AQHA, and are title sponsors of the Derby Challenge in the Bank of America Racing Challenge program.
See more AQHA Partner benefits
Please use our contact form.
Call Customer Service
American Quarter Horse Association
1600 Quarter Horse Drive
Amarillo, TX 79104